Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Unknown 2Not yet recruiting 2Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6Gastrointestinal 4Tumor-Agnostic 2Dermatologic 2Breast 2Head & Neck 1Gynecologic 1Genitourinary 1

Conditions

Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 45Paclitaxel 45Carboplatin 39Magnetic Resonance Spectroscopy 28olaparib 27Specimen Handling 26Cisplatin 24Bevacizumab 20Nivolumab 18Taxes 17Biopsy 16Gemcitabine 13Cyclophosphamide 13durvalumab 12Immunoglobulin G 11Doxorubicin 11Disulfides 11Surveys and Questionnaires 10niraparib 9liposomal doxorubicin 9dostarlimab 9Radiotherapy 8Brachytherapy 8lenvatinib 7fludarabine 7atezolizumab 7Letrozole 7Docetaxel 7cediranib 6Platinum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Immunotherapy × Gynecologic × Clear all
NCT03614949 2026-04-01

SBRT and Atezolizumab in the Management of Recurrent, Persistent, or Metastatic Cervical Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
21 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡